Chernett Jorey → Neuronetics, Inc. STIM

Item 4 is hereby amended to add the following: On April 6, 2026, the Reporting Person delivered a letter (the "Letter") to the Board of Directors of the Issuer (the "Board") calling for the immediate initiation of a comprehensive review of strategic alternatives, including the potential sale of the Issuer's transcranial magnetic stimulation ("TMS") business. In the Letter, the Reporting Person expressed the view that the Issuer's current structure and strategy are not maximizing shareholder value and that separating or divesting the TMS business should be evaluated as part of a broader strategic review. The Reporting Person also noted that such a transaction could enhance the Issuer's financial flexibility and allow for a more focused strategic direction. The Reporting Person urged the Board to engage qualified investment bankers and immediately commence a formal process to evaluate strategic alternatives. A copy of the Letter is filed as Exhibit 1 to this Amendment No. 1 and is incorporated herein by reference.